Many types of targeted therapies for lung cancer are currently available, such as epidermal growth factor receptor (EFGR) inhibitors (erlotinib and gefitinib) or anaplastic lymphoma kinase (ALK) inhibitors (crizotinib and alectinib). The gene discussed is ALK; the disease is lung carcinoma.